Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma.
Jane E RogersAlexandre A A JácomeAki OhinataRobert WolffVan K MorrisBenny JohnsonAmir MehdizadehNicole D RothschildShahab U AhmedJennifer L GuerraCathy EngPublished in: Expert review of anticancer therapy (2020)
Metastatic SCCA patients have limited options; therefore, anti-EGFR mAbs may provide benefit in the treatment armamentarium and should be further explored.
Keyphrases
- squamous cell carcinoma
- small cell lung cancer
- end stage renal disease
- epidermal growth factor receptor
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- type diabetes
- high grade
- metabolic syndrome
- patient reported outcomes
- locally advanced
- lymph node metastasis
- radiation therapy
- skeletal muscle
- combination therapy